Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Patrick Serafino who wrote (1610)	4/1/1998 4:16:00 PM
From: Frank Buck	Read Replies (2) \| Respond to of 1894

Patrick, Here is what we know presently: * AccuMed has in excess of $7 Mil. in net tangible assets * $5.2 Mil in debt has been converted to equity * In six-weeks ACMI will have serious bids for non-core assets * 2-3 weeks an announcement with Sakura will be made * A strategic marketing alliance will be announced soon with a publicly traded player * AccuMed is devoting full attention to sales and marketing of core technology and cyto has higher gross margins than micro-sales * The AcCell/TracCell increases lab throughput while simultaneously increasing the quality of the screens * Firm orders are expected in this quarter (2) '98 * Sales force has numerous sales leads from the 150 international registrants at the Chicago Cyto Seminar * The AcCell/TracCell works with liquid based prep systems * The DMC site has reported increased throughput, decreased fatigue, reduced turn-around time and other areas of improvements using the AcCell/TracCell * NeoPaths potential primary screening apparatus was an obstacle in sales to the AcCell, but has now shown to increase lab costs considerably * The AcCell Data Capture and Control Data Management System can be easily retrofit to other devices in a short amount of time * The Savant device can be sold as a research and clinical research device in areas such as cervical, bladder and pulmonary and has 30 inquiries from various organizations * Bellingham and Sakura have made a large capital commitment to a Company; technology and management * The new healthcare paradigm mandates cost control implementation * A 10 -1 reverse split will significantly reduce the amount of outstanding shares * About 38% of ACMIC shares are held by non-retail players * No competitor of AccuMed has been shown to have a clear-cut lead in the cyto-lab equipment sale field of which AccuMed is in * ACMIC has the near term potential for reinclusion on the Nasdaq National Market